Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

/PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that interim data from the single center Phase III randomized MIRAGE trial, led by UCLA, comparing...

Related Keywords

United States ,San Francisco ,California ,American ,Kishan Amarukishan ,Amar Kishan ,Prnewswire Viewray Inc ,American Society Of Clinical Oncology ,Department Of Defense ,National Institutes Of Health ,International Prostate Symptom Score ,Varian Medical Systems Inc ,Nasdaq ,Genitourinary Oncology Service ,American Society For Radiation Oncology ,Viewray Inc ,Jonsson Comprehensive Cancer Foundation ,Prostate Cancer Foundation ,Clinical Oncology ,Cancers Symposium ,Associate Professor ,Prostate Cancer ,Expanded Prostate ,Index Composite ,Linac System ,National Institutes ,American Society ,Varian Medical Systems ,Guided Radiation Therapy ,Viewray ,Nc ,